The Survival of Extra nodal Non-Hodgkin’s Lymphoma Patients in the West of Iran

Mehrdad Payandeh¹, Masoud Sadeghi^{2, 3,} , Edris Sadeghi^{2, 3} and Mehrnoush Aeinfar¹

¹Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran

²Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran

³Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

Cite this paper:
Mehrdad Payandeh, Masoud Sadeghi, Edris Sadeghi and Mehrnoush Aeinfar. The Survival of Extra nodal Non-Hodgkin’s Lymphoma Patients in the West of Iran. American Journal of Cancer Prevention. 2015; 3(5):96-99. doi: 10.12691/ajcp-3-5-6

Abstract

Background: Extra nodal Non-Hodgkin’s Lymphoma (NHL) is a heterogeneous disease in regard to geographical, ethnic, anatomic, etiological, and morphological diversities. The aim of study is evaluation of survival in extra nodal NHL patients for the first time in western Iran. Patients and Methods: Between of 2002 to 2014, fifty patients with extra nodal NHL referred to Our Clinic. We checked age, sex, histopathology reports, anatomic sites and survival for them. One representative Material of patients with diffuse large B-cell lymphoma (DLBL), Malt lymphoma, FL, SLL, anaplastic lymphoma and Burkitt’s lymphomas was re-classified after revision. The overall survival (OS) was plotted by GraphPad Prism 5 software. Results: The median age at diagnosis for the patients was 50 years (range, 13-77 years) that 26 patients (52%) had age≤ 50 years. Twenty-seven patients (54%) were male. Involvement anatomic sites were GIT, bone, abdominal, testis, skin, CNS, spleen, maxilla and adrenal gland for 19 patients(38%), 15(30%), 5(10%), 4(8%), 2(4%), 2(4%), 1(2%), 1(2%) and 1(2%), respectively. The 3-year, 5-year and 10-year survival rates are 70%, 62.2% and 60.8%, respectively. Conclusion: The OS in this study is higher than other studies and the median age is lower. Also, GIT is the most common site of involvement in extra nodal lymphomas in Middle East.

Keywords:
NHL overall survival extra nodal lymphoma DLBCL

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Newton R, Ferlay J, Beral V, Devesa SS. The epidemiology of non-Hodgkin's lymphoma: comparison of nodal and extra-nodal sites. Int J Cancer. 1997. 72 (6): 923-30.
[2]	Singh D, Kumar L, Goyal H, et al. Primary extranodal non-Hodgkin’s lymphoma in northern India. Proc Am Soc Clin Oncol. 2003. 22, 2457.
[3]	Otter R, Gerrits WB, vd Sandt MM, Hermans J, Willemze R. Primary extranodal and nodal non-Hodgkin's lymphoma. A survey of a population-based registry. Eur J Cancer Clin Oncol. 1989. 25 (8): 1203-10.
[4]	Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, et al. Helicobacter pylori infection and gastric lymphoma.N Engl J Med. 1994. 330 (18): 1267-71.
[5]	Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the majorsubtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 1998. 9 (7): 717-20.
[6]	Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006. 107 (1): 265-76. Epub 2005 Sep 8.
[7]	Arora N, Manipadam MT, Pulimood A, Ramakrishna BS, Chacko A, Kurian SS, et al. Gastrointestinal lymphomas: Pattern of distribution and histological subtypes: 10 years experience in a tertiary centre in South India. Indian J Pathol Microbiol. 2011. 54 (4): 712-9.
[8]	Khojasteh A, Haghshenass M, Haghighi P. Current concepts immunoproliferative small intestinal disease. A “Third-World lesion”. N Engl J Med. 1983. 308 (23): 1401-5.
[9]	Doglioni C, Wotherspoon AC, Moschini A, de Boni M, Isaacson PG. High incidence of primary gastric lymphoma in northeastern Italy. Lancet. 1992. 339 (8797): 834-5.
[10]	Krol AD, le Cessie S, Snijder S, Kluin-Nelemans JC, Kluin PM, Noordijk EM.. Primary extranodal no Cancer Centre West population-based NHL registry. Ann Oncol. 2003. 14 (1): 131-9.
[11]	Yaqo RT, Hughson MD, Sulayvani FK, Al-Allawi NA. Malignant lymphoma in northern Iraq:a retrospective analysis of 270 cases according to the World Health Organization classification. Indian J Cancer. 2011. 48 (4): 446-51.
[12]	Padhi S, Paul TR, Challa S, Prayaga AK, Rajappa S, Raghunadharao D, et al. Primary extra nodal non Hodgkin lymphoma: a 5 year retrospective analysis. Asian Pac J Cancer Prev. 2012. 13 (10): 4889-95.
[13]	Vose JM, Armitage JO, Weisenburger DD, Bierman PJ, Sorensen S, Hutchins M, et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol. 1988. 6 (12): 1838-44.
[14]	Cowan RA, Jones M, Harris M, Steward WP, Radford JA, Wagstaff J, et al. Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma. Br J Cancer. 1989. 59 (2): 276-82.